1Vassilev LT, Vu BT, Graves B, et ol. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 [J]. Sci- ence, 2004, 303 (5659): 844-848.
2Horvitz HR. Genetic control of programmed cell death in the nematode Caenorhabditis elegans [J]. Cancer Res, 1999, 59(7 Suppl) : 1701s-1706s.
3Jacobson MD, Weil M, Raft MC. Programmed cell death in animal development [J]. Cell, 1997, 88(3): 347-354.
4Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer devel- opment and therapy [J]. Oncogene, 2007, 26(9): 1324-1337.
5Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression [J]. Nature, 2004, 432(7015) : 307-315.
6Evan G, Littlewood T. A matter of life and cell death [J]. Sci- ence, 1998, 281(538): 1317-1322.
7Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy [J]. Cell, 2002, 108(2): 153- 164.
8Kruse JP, Gu W. Modes of p53 regulation [J]. Cell, 2009, 137 (4) : 609-622.
9Vousden KH, Prives C. Blinded by the light: the growing com- plexity of p53 [J]. Cell, 2009, 137(3): 413-431.
10Tian H, Faje AT, Lee SL, et ol. Radiation-induced phosphory- lation of Chkl at S345 is associated with p53-dependent cell cycle arrest pathways [J]. Neoplasia, 2002, 4 (2): 171-180.